Disc Medicine reports second quarter 2026 financial results
The company updated on pipeline progress, including FDA alignment for bitopertin and enrollment completion for DISC-3405 in PV.
See the latest news and media coverage for Disc Medicine. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing hematology treatments
discmedicine.comLast updated
In short: Disc Medicine navigated clinical milestones and regulatory shifts for bitopertin while reporting a stable cash runway extending into 2029.
The company updated on pipeline progress, including FDA alignment for bitopertin and enrollment completion for DISC-3405 in PV.
Disc-0974 showed consistent hepcidin reduction and robust anemia responses across all subgroups, with 55% of non-transfusion dependent patients achieving major hemoglobin response.
Cash at $730M funds into 2029. Completed Phase 3 enrollment for bitopertin in EPP; data expected Q4 2026. Updates on DISC-0974 and DISC-3405 trials.
Data from DISC-0974 trial in myelofibrosis patients with anemia will be presented at ASCO Annual Meeting on June 2, 2026.
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for...
NEW YORK, July 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf...
NEW YORK, June 29, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf...
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ...
Track Disc Medicine and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Disc Medicine and other trending companies.